BOXED WARNING Fetal toxicity: discontinue as soon as pregnancy is detected; drugs acting on the renin-angiotensin system can cause fetal injury and death.
FDA dosing
Population
Start
Target
Max
Hypertension
Adult
10 mg QD
20-40 mg QD
80 mg QD
Hypertension
Children >50 kg
5-10 mg QD
5-10 mg QD
10 mg QD
Heart failure
Adult
10 mg QD (5 mg if moderate-severe renal failure or vigorously diuresed)
20-40 mg QD
40 mg QD
Titration Increase over several weeks per response
Renal No dose adjustment based on renal function alone (clearance unchanged across renal insufficiency); use 5 mg starting dose in heart failure with moderate-severe renal failure
Hepatic Undefined
Instructions
In diuretic-treated patients, discontinue diuretic 2-3 days before starting if possible, or start 10 mg under supervision
Observe heart failure patients ≥2 hours after initial dose for hypotension
Contraindications
History of angioedema with any ACE inhibitor
Cautions
Angioedema (head/neck, and intestinal)
Anaphylactoid reactions during membrane exposure (dialysis) and desensitization
Hypotension, especially in volume/salt-depleted patients
Hyperkalemia (with potassium supplements, salt substitutes, K-sparing diuretics)
Impaired renal function
Neutropenia/agranulocytosis
Hepatic failure (cholestatic jaundice progressing to fulminant hepatic necrosis)
Cough
Adverse reactions
Cough
Dizziness
Hypotension/orthostasis
Upper respiratory symptoms
Nausea/vomiting
Pregnancy Can cause fetal injury and death; discontinue when pregnancy detected.